GHK-Cu 50mg (Copper Peptide)

GHK-Cu, the copper peptide, is a tripeptide that occurs naturally in humans. Plasma levels sit at around 200 ng/ml at age 20 and have fallen to roughly 80 ng/ml by age 60. Laboratories in several countries have established a wide range of biological actions for it: wound healing is activated, immune cells are drawn to the site, antioxidant and anti-inflammatory effects are recorded, collagen and glycosaminoglycan synthesis is stimulated in skin fibroblasts, and the growth of blood vessels is promoted. More recent work points to a part in stem cell biology and in anti-tumour defence. Its role in skin biology is what put it into cosmetics, where it is used as a reparative and anti-ageing ingredient.

GHK is the tripeptide glycyl-L-histidyl-L-lysine, a fragment of the alpha-2 macroglobulin sequence that occurs naturally in human plasma. GHK-Cu is that tripeptide complexed with copper(II). The distinction matters because the peptide and the complex are not interchangeable: the histidine imidazole nitrogen, the N-terminal amine and a backbone nitrogen form the coordination site, and much of the reported activity depends on the peptide carrying copper rather than on the peptide alone.

The most cited property is copper transport. GHK binds copper(II) with an affinity that lets it exchange with albumin, which is the main copper carrier in plasma, so the complex can move copper into and out of cells rather than simply sequestering it. Copper is a required cofactor for lysyl oxidase, which cross-links collagen and elastin, and for superoxide dismutase, so delivering copper to a site of remodelling has downstream consequences that free peptide alone would not produce.

Beyond copper delivery, GHK has been reported to act at the level of gene expression. Analyses of transcriptional data report that GHK shifts expression across large numbers of genes, with effects described on genes relevant to tissue remodelling and to nervous system function. This is the least settled part of the account: a broad transcriptional signature is easy to report and hard to attribute to a specific mechanism, and the causal chain from copper binding to the observed expression changes has not been closed.

A 2% GHK gel was trialled in 120 patients with diabetes. Ulcer closure rose from 60.8% to 98.5% and the proportion of infections fell from 34% to 7%.

The copper peptide is widely used in anti-ageing cosmetics, where it appears on ingredient lists under the INCI name Copper tripeptide-1. Several controlled facial studies have confirmed anti-ageing, firming and anti-wrinkle activity. Abdulghani et al. established that a facial cream containing GHK-Cu increased collagen in the photoaged skin of 20 female volunteers, performing better than either vitamin C or retinoic acid. Leyden et al. ran a 12 week facial study of a GHK-Cu face and eye cream and reported significant improvement in skin laxity, clarity and appearance, fewer fine lines, shallower wrinkles and greater skin density and thickness against placebo; the eye cream also outperformed a vitamin K cream. Finkley et al. studied 67 women over 12 weeks and found that the cream applied twice daily improved the appearance of aged skin, increased thickness, reduced wrinkles and strongly stimulated dermal keratinocyte proliferation, that last point determined by histological analysis of biopsies. The same study found the copper peptide to be non-toxic and non-irritating.

GHK-Cu and its analogues were found to be strong stimulators of hair growth. A synthetic analogue matched 5% minoxidil for efficiency.

Several newer lines of work have opened up the molecular actions of the copper peptide. Pollard et al. established that GHK-Cu restores function to human fibroblasts damaged by radiation treatment, which accelerates healing and the regenerative processes behind it.

Ahmed et al. demonstrated in 2005 that GHK promotes nerve regeneration. Axon regeneration was studied in collagen tubes with the peptides incorporated into them; GHK raised the production of nerve growth factors and the expression of integrins, and increased the rate at which myelinated nerve fibres regenerated.

A group at Seoul National University reported in 2009 that GHK-Cu stimulated keratinocyte proliferation and increased the expression of integrins and of p63 protein in epidermal stem cells. Since p63 is regarded both as an important stem cell marker and as an anti-senescence protein, the authors concluded that the copper peptide can revive the proliferative potential of epidermal stem cells and improve their capacity to repair tissue.

In 2010 Hong Y. et al. demonstrated that GHK-Cu reverses the expression of certain genes involved in the metastatic spread of colon cancer, and does so at very low concentration.

This is the first thing to establish for this compound, and it is checkable from the certificate. GHK is the free tripeptide, a white powder with a molecular weight of 340.38. GHK-Cu is the copper(II) complex, with a molecular weight near 401 to 403 depending on protonation state and salt form, and it is deep blue to violet because of the copper.

The colour alone is diagnostic. A material sold as GHK-Cu that arrives as a white powder is the uncomplexed tripeptide, not the complex, and no analytical instrument is needed to notice that. A certificate reporting a mass near 340 for a product named GHK-Cu is describing the free peptide.

Prezatide copper acetate is a third name in circulation and refers to the acetate salt form. Because three related materials share overlapping names and two share a CAS-adjacent identity in loose usage, the reported mass and the observed colour are more reliable identifiers here than the product name.

The copper in GHK-Cu is not a preservative or a stabiliser. It is the functional centre. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into mature matrix, and for superoxide dismutase, so copper availability at a site of remodelling is rate-limiting for those processes.

What distinguishes GHK from a simple chelator is the affinity. It binds copper tightly enough to carry it and loosely enough to exchange with albumin, the principal plasma copper carrier. A molecule that bound copper more tightly would sequester it and could plausibly do the opposite of what is claimed.

This is why results obtained with the complex should not be assumed to transfer to the free peptide, and why the transcriptional work, which is usually performed with GHK rather than GHK-Cu, sits somewhat apart from the matrix biology.

A recurring claim in this literature is that GHK resets expression across a very large number of genes. The underlying analyses are real and published, but the framing invites over-reading. Broad transcriptional signatures are a common output of expression analyses and do not by themselves demonstrate that the observed changes are caused by the peptide in the way proposed, or that they are beneficial.

The gap between the coordination chemistry, which is well characterised, and the transcriptional claims, which are correlative, is the main thing to hold in view when reading about this compound. The first supports the second only loosely.

The complex is more stable than many peptides because the tripeptide is short and has no oxidation-prone cysteine or methionine, but the copper centre introduces its own considerations. Chelating agents in a buffer will strip copper from the complex, converting it back toward free peptide, so buffer composition is not a neutral choice for this material.

Colour is a useful in-process check. Loss of the blue to violet colour on storage or on dilution into a chelating buffer indicates the complex has dissociated, which is a change in identity rather than only in purity.